A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

Plain-language summary

This study is a multi-arm trial evaluating various targeted drugs (BYL719, INC280, LDK378, MEK162) chosen by the tumor's specific molecular alterations in Chinese patients with advanced (Stage IIIB/IV) non-small cell lung cancer. It included patients with specific genetic alterations. It was a Phase 2 study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 2

Status

Completed

Sponsor

Novartis Pharmaceuticals

Intervention

BYL719, INC280, LDK378, MEK162

Start date

1/20/2015

Estimated completion

10/15/2019

Countries

China

Related genes

Locations

• Guangzhou, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Advanced (stage IIIB or stage IV) NSCLC
* Must have specific molecular alterations

Exclusion Criteria:

* Symptomatic central nervous system (CNS) metastases which are neurologically unstable or requiring increasing doses of steroids within the 4 weeks prior to study entry to control their CNS disease
* Radiation therapy within ≤ 4 weeks prior to study entry, with the exception of limited field palliative radiotherapy for bone pain relief.
* Any other malignancies within the last 5 years before study entry
* Major surgery ≤ 2 weeks prior to study entry or who have not recovered from side effects of such therapy